The Operating Theatre Journal - Journal - Page 34
The Operating Theatre Journal
Discovering the many more pages available online @ www.otjonline.com
Medtronic’s AccuRhythm AI wins
MedTech Breakthrough Award
Medtronic’s AccuRhythm AI algorithm technology has won the seventh
annual MedTech Breakthrough Awards program as the “Best New
Monitoring Solution.”
AccuRhythm AI is an artificial intelligence algorithm that improves
the accuracy of heart rhythm event data from the Medtronic LINQ
II insertable cardiac monitor (ICM) so physicians can better care for
people with abnormal heart rhythms. The Medtronic AI technology was
a standout from a field of nearly 4,000 nominations globally.
MedTech Breakthrough, an independent market intelligence organisation
that recognises the top companies, technologies and products in the
global health and medical technology market, conducts the MedTech
Breakthrough Awards program. The LINQ family of insertable cardiac
monitors (ICMs) provide continuous, long-term monitoring for patients
with increased risk of abnormal heart rhythms who experience
infrequent symptoms including dizziness, palpitations, syncope
(fainting) and chest pain, thereby requiring long-term monitoring or
ongoing management.
Stacey Churchwell, vice president and general manager of the
Cardiovascular Diagnostics and Services business within the Cardiac
Rhythm Management Operating Unit, said: “We are thrilled to win
the MedTech Breakthrough Award for a technology that makes such
a profound impact on patients and helps clinicians focus on cardiac
events that are most relevant. We look forward to building on this AI
technology with future enhancements across our LINQ family of ICMs.”
Medtronic introduced AccuRhythm AI algorithms in 2022 to patients and
clinicians in Australia, countries throughout Europe, the United States,
and New Zealand to help improve the accuracy of information physicians
receive so they can better treat their patients. The two AI algorithms
— specific to the most common ICM false alerts, atrial fibrillation (AF)
and pause (asystole) — have been shown to reduce the number of false
alerts by as much as 84%, saving clinicians approximately 319 hours
of
clinic review time annually (for every 200 LINQ II patients).
An enhancement to the AF algorithm for the LINQ II ICM further reduces
AF false alerts, which is anticipated to further reduce clinic review
time.
Source: MED-TECH INNOVATION News
Further reading: https://bit.ly/OTJAccuRAI
inHEART RECEIVES CE CERTIFICATION
UNDER NEW MDR FOR NOVEL, AIBASED, DIGITAL TWIN OF THE HEART
inHEART solution creates digital 3D models of the heart with
unprecedented anatomical details, allowing physicians to better plan
and personalize cardiac ablation procedures
inHEART, a privately-held medical device company delivering the
world’s most advanced digital twin of the patient’s heart, announced on
May 18th that it has received CE certification under the new European
Medical Device Regulation (MDR 2017/745) for its inHEART MODELS
software suite that enables 3D visualization and analysis of anatomical
structures for image-guided cardiac ablations. With this certification,
inHEART will deliver fully automated segmentation of medical images
with a new software module based on machine-learning technology to
European customers. In addition, this certification will facilitate a swift
pace of ongoing software enhancements.
Additional features of the inHEART solution already available in the US
and now available in Europe with the new CE Mark MDR certification
include new information (scar transmurality and left atrium wall
thickness), new visualization and measurement tools, and an enhanced
user experience.
“inHEART remains committed to delivering solutions that meet or
exceed the highest quality and regulatory standards,” said Todor
Jeliaskov, President and CEO of inHEART. “With this CE Mark MDR
certification, we demonstrate our commitment to provide physicians
with 3D cardiac models they can trust to help them determine the
optimal treatment plan for each unique patient. I am proud of the
inHEART team and their commitment to this level of excellence.”
The inHEART solution aims to address many of the challenges of
conventional cardiac ablations with its proprietary segmentation
algorithm that analyzes preprocedural CT and/or MR images to create
highly detailed, interactive 3D models of the heart. This information
allows physicians to optimize treatment strategies for cardiac ablation
procedures based on each patient’s unique cardiac anatomy and
supports pre-procedural planning and seamless integration into all
major electroanatomic mapping (EAM) systems.
Early clinical evaluations have shown a potential to reduce VT procedure
times by 60% as compared to the conventional approach (from 5 hours
to less than 2 hours). Shorter procedures are typically associated with
superior safety and patient experience. In addition, these evaluations
have demonstrated the potential for image-guided ablations to reduce
failure rate by 38%, as compared to the conventional approach.1
twitter.com/OTJOnline
1 Data on file
Further information: https://www.inheartmedical.com/
34
THE OPERATING THEATRE JOURNAL
www.otjonline.com